Results 11 to 20 of about 8,113 (209)

Wound, pressure ulcer, and burn guidelines (2023)-4: Guidelines for the management of connective tissue disease/vasculitis-associated skin ulcers, third edition. [PDF]

J Dermatol
The Journal of Dermatology, Volume 52, Issue 6, Page e430-e480, June 2025.
Asano Y, Asai J, Ishii T, Iwata Y, Kodera M, Miyabe C, Uchiyama A, Ogawa Y, Okamura K, Kishibe M, Koike Y, Kotobuki Y, Fujimoto N, Miyagi T, Yamaguchi Y, Yoshizaki A, Omori R, Nakanishi T, Fujiwara H, Maekawa T, Motegi SI, Yoshino Y, Hasegawa M, Fujimoto M, Tachibana T, Wound, Pressure Ulcer, and Burn Guidelines Drafting Committee (connective tissue disease/vasculitis group).   +27 more
europepmc   +2 more sources

Portopulmonary hypertension practice patterns after liver transplantation

Liver Transplantation, EarlyView., 2022
Abstract Portopulmonary hypertension (POPH) is a type of pulmonary arterial hypertension occurring exclusively in those with portal hypertensive liver disease. Liver transplantation (LT) can significantly improve outcomes. Current guidelines counsel against immediate adjustments to targeted therapy after LT and suggest routine echocardiography as ...
Arun Jose, Elizabeth J. Kopras, Shimul A. Shah, Jean M. Elwing   +3 more
wiley   +1 more source

CAQ Corner: Basic concepts of transplant immunology

, 2022
Liver Transplantation, EarlyView.
Amanda Cheung, Josh Levitsky
wiley   +1 more source

Co-inhibition of Angiotensin II Receptor and Endothelin-1 Attenuates Renal Injury in Unilateral Ureteral Obstructed Mice

Kidney & Blood Pressure Research, 2016
Background/Aims: Both endothelin-1 (ET-1) and the renin-angiotensin system (RAS) may play important roles in renal fibrosis in the obstructed kidney.
Yoon-Kyung Chang, Hyunsu Choi, Jin Young Jeong, Ki-Ryang Na, Kang Wook Lee, Dae Eun Choi   +5 more
doaj   +1 more source

Distinct ETA receptor binding mode of macitentan as determined by site directed mutagenesis. [PDF]

PLoS ONE, 2014
The competitive endothelin receptor antagonists (ERA) bosentan and ambrisentan, which have long been approved for the treatment of pulmonary arterial hypertension, are characterized by very short (1 min) occupancy half-lives at the ET(A) receptor.
John Gatfield, Celia Mueller Grandjean, Daniel Bur, Martin H Bolli, Oliver Nayler   +4 more
doaj   +1 more source

Effect of bosentan therapy in persistent pulmonary hypertension of the newborn

Pediatrics and Neonatology, 2018
Background: Persistent pulmonary hypertension of the newborn (PPHN) contributes to neonatal hypoxemia and is associated with a high mortality. Some PPHN patients are unresponsive to inhaled nitric oxide (iNO).
Gunlawadee Maneenil, Anucha Thatrimontrichai, Waricha Janjindamai, Supaporn Dissaneevate   +3 more
doaj   +1 more source

Efficacy and safety of novel-targeted drugs in the treatment of pulmonary arterial hypertension: a Bayesian network meta-analysis

Drug Delivery, 2021
Background: Pulmonary arterial hypertension (PAH) is a severe and fatal clinical syndrome characterized by high blood pressure and vascular remodeling in the pulmonary arterioles, which is also a rapidly progressing disease of the lung vasculature with a
Wenhai Fu, Wenjun He, Yuexin Li, Yangxiao Chen, Jingyi Liang, Hui Lei, Lin Fu, Yanghang Chen, Ni Ren, Qian Jiang, Yi Shen, Ran Ma, Tao Wang, Xinni Wang, Nuofu Zhang, Dakai Xiao, Chunli Liu   +16 more
doaj   +1 more source

Case Report: Bosentan and Sildenafil Exposure in Human Milk - A Contribution From the ConcePTION Project

Frontiers in Pharmacology, 2022
Introduction: Quantitative information on disposition of maternal medicines in human milk remains a major knowledge gap. This case report presents the clinical and pharmacokinetic data of a single mother-infant pair exposed to bosentan and sildenafil for
Nina Nauwelaerts, Michael Ceulemans, Michael Ceulemans, Michael Ceulemans, Neel Deferm, An Eerdekens, Bart Lammens, Yeghig Armoudjian, Kristel Van Calsteren, Kristel Van Calsteren, Karel Allegaert, Karel Allegaert, Karel Allegaert, Karel Allegaert, Loes de Vries, Pieter Annaert, Pieter Annaert, Anne Smits, Anne Smits, Anne Smits   +19 more
doaj   +1 more source

Bosentan and oral anticoagulants in HIV patients: what we can learn of cases reported so far

Hematology Reports, 2011
Pulmonary arterial hypertension is an infrequent but nevertheless serious life-threatening severe complication of HIV infection. It can be treated with bosentan and oral anticoagulants.
José Antonio Morales-Molina, Juan Enrique Martínez-de la Plata, Olivia Urquízar-Rodríguez, María Angustias Molina-Arrebola   +3 more
doaj   +1 more source

Cost Effectiveness of Bosentan for Pulmonary Arterial Hypertension: A Systematic Review

Canadian Respiratory Journal, 2018
Objectives. Although many studies have reported on the cost-effectiveness of bosentan for treating pulmonary arterial hypertension (PAH), a systematic review of economic evaluations of bosentan is currently lacking.
Ruxu You, Xinyu Qian, Weijing Tang, Tian Xie, Fang Zeng, Jun Chen, Yu Zhang, Jinyu Liu   +7 more
doaj   +1 more source